Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAK | O14976 | 5/20 | 0.44 |
| ▸ | RIPK2 | O43353 | 3/20 | 0.44 |
| ▸ | NLK | Q9UBE8 | 2/20 | 0.44 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.44 |
| ▸ | ABL1 | P00519 | 1/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | EPHA1 | P21709 | 1/20 | 0.44 |
| ▸ | EPHA8 | P29322 | 1/20 | 0.44 |
| ▸ | TXK | P42681 | 1/20 | 0.44 |
| ▸ | COQ8A | Q8NI60 | 1/20 | 0.44 |
| ▸ | SLC22A12 | Q96S37 | 2/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | STK16 | O75716 | 1/20 | 0.44 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.44 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.44 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.44 |
| ▸ | CCNC | P24863 | 1/20 | 0.43 |
| ▸ | CDK8 | P49336 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.40 |
| ▸ | AXL | P30530 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19643620 | 0.89 | GAK (0.44) | GAKAAK1KDRDYRK3PRKD3 | |
| SCHEMBL591544 | 0.84 | IDO1 (0.45) | GAKSLC22A12CCNCCDK8AXL | |
| SCHEMBL12367211 | 0.83 | HTR1A (0.41) | SLC22A12CDK8PRKD3CDK1CDK2 | |
| SCHEMBL26632797 | 0.83 | NR4A2 (0.45) | GAKRIPK2NLKABL1COQ8A | |
| SCHEMBL3851998 | 0.83 | SLC22A12 (0.56) | GAKRIPK2NLKEPHB6ABL1 | |
| SCHEMBL632944 | 0.81 | LMNA (0.52) | GAKRIPK2NLKCOQ8ASLC22A12 | |
| SCHEMBL2594936 | 0.81 | GAK (0.47) | GAKRIPK2SLC22A12KDRMAPK14 | |
| SCHEMBL3576735 | 0.80 | KDR (0.40) | SLC22A12KDRMAPK14BRAFTNNI3K | |
| SCHEMBL6590113 | 0.79 | GAK (0.64) | GAKRIPK2NLKEPHB6ABL1 | |
| SCHEMBL4853499 | 0.79 | SLC2A1 (0.42) | SLC22A12AXLIDO1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220213114-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2022-07-07 | — | — | US | disclosed |
| US-20220213114-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2022-07-07 | — | — | US | disclosed |
| US-11312723-B2 | Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases | THE ROCKEFELLER UNIVERSITY (US) | 2022-04-26 | — | — | US | disclosed |
| US-11312723-B2 | Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases | THE ROCKEFELLER UNIVERSITY (US) | 2022-04-26 | — | — | US | disclosed |
| US-20200369677-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2020-11-26 | — | — | US | disclosed |
| US-20200369677-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | THE ROCKEFELLER UNIVERSITY (US) | 2020-11-26 | — | — | US | disclosed |
| EP-3716972-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | The Rockefeller University (US) | 2020-10-07 | — | — | EP | disclosed |
| CN-111670034-A | Pyranopyrazoles and pyrazolopyridines immunomodulators for the treatment of autoimmune diseases | 洛克菲勒大学 | 2020-09-15 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369677-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | TFPI, TFPI2, SERPINC1 | GAK 2265/4885RIPK2 620/4885NLK 3072/4885 |
| US-11312723-B2 | Pyranopyrazole and pyrazolopyridine immunomodulators for treatment of autoimmune diseases | TFPI, TFPI2, SERPINC1 | GAK 2265/4885RIPK2 620/4885NLK 3072/4885 |
| US-20220213114-A1 | PYRANOPYRAZOLE AND PYRAZOLOPYRIDINE IMMUNOMODULATORS FOR TREATMENT OF AUTOIMMUNE DISEASES | TFPI, TFPI2, SERPINC1 | GAK 2265/4885RIPK2 620/4885NLK 3072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.